Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Sleep Bruxism (BRUX-XIT)
NCT04792398Phase 4Unknown
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in sleep bruxism. Primary endpoints: Change of maximum EMG amplitudes and Verbal Rating Scale of Global impression of change at day 154. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
sleep bruxism
Beyond the preview
Go deeper on NCT04792398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792398.